AstraZeneca Halts Combined Trials of Two Lung Cancer Drugs Due to Safety Issues

London-based drug firm has paused the tests due to an increase in the incidence of interstitial lung disease-like reports. No deaths have been reported.

Following reports of lung disease in some patients, AstraZeneca has temporarily halted two clinical trials combining experimental drugs to treat lung cancer, said the company.

The company stopped tests that combined its AZD9291 compound with durvalumab to treat patients with advanced non-small cell lung cancer after an increase in the incidence of interstitial lung disease-like reports, spokeswoman Esra Erkal-Paler said by e-mail, confirming a note to investors from Goldman Sachs Group Inc.

AstraZeneca Inks Agreement with Roche, Qiagen for New Blood-based Cancer Drug Tests
AstraZeneca has signed an agreement with Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to find out patients who will benefit from its lung cancer drugs

A spokeswoman said the tests had been paused due to an increase in the incidence of interstitial lung disease-like reports. No deaths have been reported as a result of the problem. Patients in the trials will get updated consent forms before deciding whether to continue in the studies.

AZD9291 and durvalumab are two of AstraZeneca's most promising experimental cancer treatments, although their use together in lung disease is only one of many possible applications.

The news may limit Astra’s ability to combine AZD9291 with other drugs and benefit U.S. rival Clovis Oncology Inc., which is developing a competing drug called rociletinib, Terence Flynn, an analyst at Goldman Sachs, said in the note.

AstraZeneca Initiates Phase III Program for Selumetinib
AstraZeneca revealed that it began late stage trials for its investigative MEK inhibitor selumetinib.

Shares of AstraZeneca dropped 0.2 percent to 4,150.50 pence as of 9:35 a.m. in London trading.

Source-Medindia

Takeover Bid of AstraZeneca Given Up by Drugmaker Pfizer
Takeover bid of British AstraZeneca was given up by the US drugmaker Pfizer after its final $117-billion offer was rejected last week, the latter said on Monday.

Merger Tussle Between Drugs Giants Pfizer, AstraZeneca With $100 Bn Deal
An informal approach worth almost $100 billion between US drugs giant Pfizer entering into merger with British rival AstraZeneca will fuel cancer research.